Literature DB >> 3350281

Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief.

A P Archambault1, P Pare, R J Bailey, H Navert, C N Williams, H J Freeman, S J Baker, N E Marcon, R H Hunt, L Sutherland.   

Abstract

We conducted a double-blind, randomized, parallel group study in 169 patients with acute duodenal ulcers to compare omeprazole, 20 mg daily, with cimetidine, 600 mg twice daily. After 2 wk, 58% of the omeprazole-treated patients and 46% of the cimetidine-treated patients were completely healed (p = 0.056). After 4 and 6 wk 84% and 88% healed with omeprazole, and 80% and 89% healed with cimetidine (p = NS). After 2 wk, pain was completely gone in 62% of the omeprazole-treated patients versus 46% of the cimetidine-treated patients (p = 0.04). Clinical or laboratory adverse events were reported in 6 (7%) of the omeprazole-treated patients and 11 (13%) of the cimetidine-treated patients (p = NS). An adverse event caused withdrawal of 1 patient on omeprazole (anxiety and depression) and 2 patients on cimetidine (diarrhea and fall in hemoglobin). We conclude that omeprazole (20 mg daily) resulted in a trend toward more rapid ulcer healing compared with a relatively high dose of cimetidine (600 mg b.i.d.), and was preferred by patients for relief of ulcer pain.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3350281     DOI: 10.1016/0016-5085(88)90003-0

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  16 in total

Review 1.  Clinical pharmacology and therapeutics.

Authors:  M J Kendall; R C Horton
Journal:  Postgrad Med J       Date:  1990-03       Impact factor: 2.401

2.  Effect of omeprazole on gastric first-pass metabolism of ethanol.

Authors:  R Roine; R Hernández-Muñoz; E Baraona; R Greenstein; C S Lieber
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

3.  Omeprazole versus placebo in duodenal ulcer healing. The United States experience.

Authors:  D Y Graham; A McCullough; M Sklar; S J Sontag; W M Roufail; R C Stone; R H Bishop; N Gitlin; A J Cagliola; R S Berman
Journal:  Dig Dis Sci       Date:  1990-01       Impact factor: 3.199

Review 4.  Omeprazole. Overview and opinion.

Authors:  S Holt; C W Howden
Journal:  Dig Dis Sci       Date:  1991-04       Impact factor: 3.199

Review 5.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

Review 6.  Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers.

Authors:  M Deakin; J G Williams
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

7.  Comparative tolerability profile of omeprazole in clinical trials.

Authors:  T J Simon; D C Bradstreet
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

8.  Effect of intermittent administration of omeprazole on serum pepsinogens in duodenal ulcer patients and healthy volunteers.

Authors:  I Biemond; L F Crobach; J B Jansen; C B Lamers
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

9.  Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy.

Authors:  V Savarino; G S Mela; P Zentilin; P Cutela; M R Mele; S Vigneri; G Celle
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

Review 10.  Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.

Authors:  P Richardson; C J Hawkey; W A Stack
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.